The stock is trading near the $135.11 acquisition price, leaving limited upside but a low-risk arbitrage for deal completion. Monitor shareholder vote and regulatory approvals; any deal termination risk would cause steep downside. The Phase 2 zumilokibart data supports the acquisition rationale but is now academic given the fixed cash exit.
Price Chart
Executive Summary
Apogee Therapeutics reported Q2 2026 results but the quarter's significance is completely overshadowed by AbbVie's pending acquisition of Apogee for $135.11 per share in cash, representing a total equity value of approximately $10.9 billion. The transaction, expected to close in Q3 2026, provides a clear exit value for shareholders. The quarterly financials show a pre-revenue clinical-stage biotech with net loss of $85.9M and cash of $1.3B, which are immaterial given the acquisition premium.
Key Facts
- AbbVie to acquire Apogee for $135.11 per share in cash, total equity value ~$10.9B
- Transaction expected to close in Q3 2026, subject to shareholder and regulatory approvals
- Positive Phase 2 APEX Part B results for zumilokibart in atopic dermatitis met all endpoints
- Cash position of $1.3B as of June 30, 2026, up from $621.2M a year ago
- Net loss of $85.9M for Q2 2026 vs $66.1M in Q2 2025
- Strategic financing collaboration with Blackstone Life Sciences for up to $1.3B in non-dilutive capital
Financial Impact
Acquisition at $135.11/share implies ~7% premium over current market cap of $10.2B, with shareholders receiving cash exit
Risk Factors
- Deal fails to close due to regulatory or shareholder rejection
- AbbVie terminates agreement under material adverse change clause
- Competing bid or antitrust challenges delay or block transaction
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3341678 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 15-12G | — | awaiting T+5 | — | — |
Sep 3, 2026 29d ago | 25-NSE | $135.06 awaiting T+5 | awaiting T+5 | — | — |
Sep 3, 2026 29d ago | 8-K | $135.06 awaiting T+5 | awaiting T+5 | — | — |
Aug 11, 2026 7w ago | 8-K | $134.55 $134.71 | ▲ +0.12% | ▲ +0.56% | — |
Aug 10, 2026 7w ago | 8-K | $134.65 $134.59 | ▼ −0.04% | ▲ +0.00% | — |
Aug 10, 2026 7w ago | Press Release | $134.65 $134.59 | ▼ −0.04% | ▲ +0.00% | — |
Aug 6, 2026 8w ago | Institutional Cluster | $134.49 $134.45 | ▼ −0.03% | ▼ −1.24% | — |
Aug 3, 2026 8w ago | DEFA14A | $134.19 $134.69 | ▲ +0.37% | ▲ +0.47% | — |
Jul 11, 2026 11w ago | Insider Cluster | $133.82 $134.00 | ▲ +0.13% | ▲ +0.92% | — |
Jun 26, 2026 13w ago | DEFA14A | $132.61 $133.50 | ▲ +0.67% | ▼ −0.72% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access